Please login to the form below

Not currently logged in
Email:
Password:

EC appoints rare disease expert committee

The European Commission has listed the members of the European Union Committee of Experts on Rare Diseases (EUCERD)

The European Commission (EC) has listed the members of the European Union Committee of Experts on Rare Diseases (EUCERD), following four calls for expressions of interest.

The Commission made the formal decision to establish EUCERD on November 30, 2009 (2009/872/EC), replacing the previous organisation, the Rare Diseases Task Force (RDTF).

The new body comprises 51 members drawn from patient organisations, the pharmaceutical industry and representatives of past and present EC projects in rare diseases. These members will work with one representative of each of the 27 EC Member States and a representative of the European Centre for Disease Prevention and Control (ECDC).

The new appointees come from the European rare disease portal Orphanet, European patient organisation EURORDIS, academic and research institutions throughout Europe, and pharmaceutical companies working to develop rare disease products, including Genzyme, Celgene, Orphan Europe and Baxter.

The remit of the EUCERD is to assist the EC with the preparation and implementation of Community activities in the field of rare diseases, in co-operation and consultation with specialist bodies in Member States, relevant European authorities and other relevant stakeholders, as well as fostering exchanges of relevant experience, policies and practices between the parties.

4th August 2010

Share

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
The rise of digital healthcare – fuelled by open innovation in healthtech hubs
How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...